Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8515153 | 1.00 | KDM4E (0.58) | KDM4EKDM4CGRIN1GRIN2AGRIN2B | |
| SCHEMBL8513622 | 0.97 | KDM4E (0.58) | KDM4EKDM4CGRIN1GRIN2AGRIN2B | |
| SCHEMBL8515103 | 0.92 | KDM4E (0.49) | KDM4EKDM4CSMYD3EPHX2NAMPT | |
| Acetone SCHEMBL28835039 | 0.90 | KDM4E (0.50) | KDM4EKDM4CEPHX2MAPK8NAMPT | |
| SCHEMBL9605892 | 0.84 | KDM4E (0.60) | KDM4EKDM4CGRIN1GRIN2AGRIN2B | |
| SCHEMBL13349296 | 0.83 | POLB (0.50) | KDM4EKDM4CPOLBEPHX2NAMPT | |
| SCHEMBL8516129 | 0.82 | KDM4E (0.49) | KDM4EKDM4CGRIN1GRIN2AGRIN2B | |
| SCHEMBL16688446 | 0.82 | MAPK1 (0.61) | KDM4EPOLBNAMPT | |
| SCHEMBL31365939 | 0.82 | L3MBTL1 (0.57) | KDM4ESMN1; SMN2EPHX2 | |
| SCHEMBL12364920 | 0.81 | EPHX2 (0.60) | KDM4ESMN1; SMN2EPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643301-B1 | TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PF MEDICAMENT (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-2643301-B1 | TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PF MEDICAMENT (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-2643301-A1 | TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | Pierre Fabre Medicament (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-20130171067-A1 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130171067-A1 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012069608-A1 | TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171067-A1 | TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS | SLC40A1, CDC73, BRCA1 | KDM4E 4131/4885KDM4C 3844/4885GRIN1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.